Latest news with #Mallinckrodt
Daily Mail
7 days ago
- Health
- Daily Mail
Families devastated as neighborhood cancer surge is traced to radioactive waste from first atomic bomb
A chilling new study has confirmed the fears of generations - that children who grew up near a Missouri creek polluted by nuclear waste from the first atomic bomb project are suffering from elevated rates of cancer rates. The findings have been published this week in JAMA Network Open by researchers at the Harvard T.H. Chan School of Public Health and provide the clearest evidence to date linking radioactive contamination in Coldwater Creek, a tributary of the Missouri River north of St. Louis, to long-term cancer risks in nearby residents. 'Our research indicates that the communities around North St. Louis appear to have had excess cancer from exposure to the contaminated Coldwater Creek,' said Marc Weisskopf, professor of environmental epidemiology and physiology at Harvard and corresponding author of the study. Weisskopf's team found that individuals who lived within one kilometer of the creek as children between the 1940s and 1960s were significantly more likely to develop cancer later in life. They believe the cancer is a result of ionizing radiation exposure from the creekbed, soil, and water. The source of the contamination dates back to one of the darkest and most secretive chapters in US history: the Manhattan Project, the clandestine federal initiative that developed the world's first nuclear weapons. Mallinckrodt Chemical Works, operating in downtown St. Louis, was responsible for processing uranium used in the atomic bomb dropped on Hiroshima in 1945. But after the war, barrels of radioactive waste were moved to open-air storage sites near Coldwater Creek, where they remained for years, exposed to rain, wind, and runoff. Those toxins, including uranium and thorium, leached into the soil and water, contaminating the surrounding environment and putting thousands at risk, especially children, who played in the creek, dug in the dirt, and breathed in radioactive dust kicked up during gardening or construction. Now, decades later, the health toll is becoming undeniable. The Harvard study, based on a cohort of 4,209 individuals who lived in the Greater St. Louis area between 1958 and 1972, found that 24% reported having cancer. Among those living closest to the creek, that number rose to 30%. 'Our study found that children in the 1940s to 1960s who lived near Coldwater Creek… had a 44% higher risk of cancer compared to those living further than 20 kilometers away,' said co-author Michael Leung, a postdoctoral fellow at Harvard's Department of Environmental Health, to Fox News. The types of cancer reported include leukemia, thyroid, breast, and colon cancers are consistent with illnesses linked to radiation exposure. For many in North St. Louis County, the revelation is both vindicating and heartbreaking. Families who grew up splashing in Coldwater Creek or building homes nearby have lost loved ones to aggressive cancers - often with no explanation, until now. The Harvard study suggests those deaths were not random but the byproduct of wartime secrecy, industrial negligence, and decades of environmental inaction. While the researchers acknowledged limitations in their study, including its sample size and reliance on self-reported outcomes, the statistical signal is clear enough to prompt renewed concern and action. The study comes at a pivotal moment. Last month, Congress passed an expanded version of the Radiation Exposure Compensation Act (RECA) as part of President Trump's 'Big Beautiful Bill,' offering financial relief for Americans harmed by nuclear testing and contamination - including, for the first time, residents near Coldwater Creek. 'These findings may have broader implications - as countries think about increasing nuclear power and developing more nuclear weapons,' Weisskopf warned. 'The waste from these entities could have huge impacts on people's health, even at these lower levels of exposure.' Local families, activists, and health officials have long urged the government to take the cancer clusters seriously. In July 2023, an investigation published by The Associated Press, The Missouri Independent and MuckRock showed that the federal government and companies responsible for nuclear bomb production and atomic waste storage sites in the St. Louis area were aware of health risks, spills, improperly stored contaminants and other problems but often ignored them. The federal government formally acknowledged the contamination at Coldwater Creek in the 1980s, but efforts to clean up the area have been slow and piecemeal. Now, armed with hard scientific evidence, those affected are hoping for accountability. 'We hope these findings will support public health measures for affected communities, as well as ongoing efforts to remediate the creek,' Leung said. While nuclear workers had direct exposure, people who live near contamination sites worry about uncertainty. Many who grew up in the area weren't told about the risks for decades. In 2007, Chapman and Karen Nickel were so concerned about cancer and other unusual illnesses in their St. Louis County neighborhoods that they formed Just Moms STL. In 2019, the federal Agency for Toxic Substances and Disease Registry issued a report that found people who regularly played in Coldwater Creek as children from the 1960s to the 1990s may have a slight increased risk of bone cancer, lung cancer and leukemia. The agency determined that those exposed daily to the creek starting in the 2000s, when cleanup began, could have a small increased risk of lung cancer. The government's sloppy handling of nuclear contamination over decades has understandably made people doubt official promises that conditions are safe now, said Arjun Makhijani, a nuclear expert and president of the Institute for Energy and Environmental Research. 'There is zero trust,' he said. People in the St. Louis area are concerned that more illnesses are caused by the contamination and some are pushing for legislation to compensate those who are sick. Others have sued those responsible for the waste. Several people with serious illnesses, or whose loved ones are sick, met recently at Nickel's house. Jim Gaffney, now in his 60s, grew up in the 1960s playing in Coldwater Creek - his childhood home backed up to the waterway. 'I was always in the creek,' Gaffney said. 'Told not to, but we had seven kids. Mom couldn't watch us all. We just thought it was fun. We built mudslides and everything. I'm sure I got exposed.' He and his wife, Susie, loved the neighborhood so much that when they got married, they moved into a home there. Their children grew up playing in a park that backs to the creek, Susie Gaffney said. 'We had no warnings. We had no fears,' she said. Jim Gaffney was diagnosed with Stage 4 Hodgkin lymphoma in 1981 and given little chance to survive. A bone-marrow transplant saved his life, but the toll of the radiation, chemotherapy and the disease has been enormous. 'Now I've got hypertension, heart failure, I've had at least five bladder tumors removed since ´95. I'm still here, but it's not been easy,' he said. The Gaffneys' son Joe has battled thyroid cancer since 1998 when he was 18. Tricia Byrnes swam in Weldon Spring quarries as a teenager. Eight years ago, her 15-year-old son was diagnosed with a rare cancer of the thymus, a small organ near the heart. She wonders about a connection. Byrnes she became so frustrated with the lack of acknowledgement about the health risk at Weldon Spring that she successfully ran as a Republican for the Missouri House, where she is pushing for federal compensation for those who believe their illnesses are connected to contamination. She said it's infuriating that the federal government not only allowed the contamination that made people sick, but didn't do enough to contain it. 'What the hell is wrong with people?' she asked.
Yahoo
18-06-2025
- Health
- Yahoo
Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
– Survey findings showed a majority of participants had a favorable experience injecting Acthar Gel via SelfJect, with a high level of satisfaction, confidence, convenience, and ease of use regarding the injector¹ – DUBLIN, June 18, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a survey assessing patient perceptions of their experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector ("SelfJect"). SelfJect is a single-dose pre-filled injector designed for the administration of Acthar Gel in appropriate patients.² It is approved by the U.S. Food and Drug Administration (FDA) for patients with a range of chronic and acute inflammatory conditions.² The survey collected data on patient perceptions of satisfaction, confidence, convenience, and ease of use, as well as perceptions of anticipated persistence and compliance.¹ The manuscript was recently published online in Advances in Therapy. Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides.² Acthar Gel is approved by the FDA for the treatment of several autoimmune disorders and medical conditions known to cause inflammation.² SelfJect is available in 40 USP units/0.5 mL and 80 USP units/1.0 mL injectors and must be administered by adults (18 years of age or older).² SelfJect is not to be used for the treatment of infantile spasms.² Please see Indications and Important Safety Information for Acthar Gel below. "Real-world perceptions are critical to capturing patient satisfaction and treatment experience with SelfJect beyond clinical trials, especially for those living with conditions that can often be challenging to manage," said George Wan, Ph.D., M.P.H., Vice President, Evidence Generation and Data Sciences, Mallinckrodt. "Findings from this cross-sectional patient survey enhance our understanding on the use of Acthar Gel via SelfJect in appropriate patients." "Patients, particularly those with chronic or acute inflammatory and autoimmune conditions who may experience dexterity and/or visual challenges, need access to delivery devices they feel are easy and convenient to use," said Steven Taylor, President and CEO, Arthritis Foundation. "This is why rigorous, independent evaluation is required for products and packaging to earn our Ease of Use® certification. We appreciate the work of organizations like Mallinckrodt, whose dedication to advancing therapies drives meaningful progress for people impacted by these conditions." About the Survey "Real-World Insights on Patient Satisfaction and Experience with Acthar Gel via SelfJect (RISE™): A Cross-Sectional Patient Survey" utilized a validated form and was conducted among a cross-section of patients to assess their experience with SelfJect.¹ The survey, conducted between November 2024 and January 2025, collected data from 54 participants with a mean age of 55.4 years.¹ The majority of participants were female 76% (n=41/54), and identified as White/Caucasian 74% (n=40/54) and non-Hispanic/non-Latino 83% (n=45/54).¹ Eligible participants were aged ≥18 years, had a diagnosis of an indication of Acthar Gel based on the prescribing information, and had used Acthar Gel via SelfJect for ≥6 self-injections at the time of the survey.¹ Additionally¹: 33% (n=18/54) reported chronic or recurring ocular inflammatory disease, and 26% (n=14/54) had rheumatoid arthritis 39% (n=21/54) reported dexterity or visual problems 39% (n=21/54) reported having previously used Acthar Gel multi-dose vial and syringe In this survey, participants reported a favorable experience injecting Acthar Gel via SelfJect, highlighting high levels of satisfaction, confidence, convenience, and ease of use regarding the injector.¹ Participants also reported perceptions of anticipated positive persistence and compliance with the device, which may correlate with improved continuity of care.¹ Findings from this survey included¹: 91% (n=49/54) reported they were satisfied or very satisfied injecting Acthar Gel via SelfJect overall 89% (n=48/54) felt very or extremely confident administering Acthar Gel via SelfJect to themselves at home 91% (n=49/54) found SelfJect to be convenient or very convenient 100% (n=54/54) felt that it was moderately, very or extremely easy to self-inject with SelfJect 87% (n=47/54) responded that they were likely or very likely to continue taking Acthar Gel via SelfJect for the prescribed period, and 87% (n=47/54) also responded that they were likely or very likely to maintain compliance for the prescribed period, with respect to timing, dosage, and frequency Summary of limitations of the survey include¹: Data collected from the questionnaire are cross-sectional and do not provide long-term information on patient satisfaction. Persistence and compliance were assessed based on participant perceptions rather than objective, longitudinal measurement. Future research using longitudinal designs is needed to evaluate these factors accurately. Response bias may be present as the findings rely on survey participants' subjective experiences with the device. This descriptive study characterizes the experience of survey participants with an alternative delivery device; therefore, it does not include direct comparisons of Acthar Gel via SelfJect with other self-injection devices. This survey was sponsored by Mallinckrodt Pharmaceuticals. INDICATIONS Acthar Gel is indicated for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis) and systemic lupus erythematosus Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis Symptomatic sarcoidosis Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus Treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age IMPORTANT SAFETY INFORMATION Contraindications Acthar is contraindicated: For intravenous administration In infants under 2 years of age who have suspected congenital infections With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin Warnings and Precautions The adverse effects of Acthar are related primarily to its steroidogenic effects Acthar may increase susceptibility to new infection or reactivation of latent infections Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy Adverse Reactions Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve Pregnancy Acthar may cause fetal harm when administered to a pregnant woman Please see full Prescribing Information for additional Important Safety Information. About Mallinckrodt Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including with regard to Acthar Gel (repository corticotropin injection), the Acthar Gel Single-Dose Pre-filled SelfJect™ Injector, the potential of these products to improve health and treatment outcomes, and their potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of Mallinckrodt's recent emergence from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with Acthar Gel and Acthar Gel Single-Dose Pre-filled SelfJect Injector; and other risks identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. CONTACT Media InquiriesGreen Room Communications908-577-4531mediainquiries@ Investor RelationsBryan ReasonsExecutive Vice President and Chief Financial Mallinckrodt, the "M" brand mark, SelfJect, and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. ©2025 Mallinckrodt. US-2500288 06/25 References ¹ Bindra J., Chopra I., Hayes K., et al. Real-World Insights on Satisfaction and Experience with Acthar Gel via SelfJect (RISE™): A Cross-Sectional Patient Survey. Advances in Therapy. 2025. Acthar® Gel (repository corticotropin injection) [Prescribing Information]. Bridgewater, NJ: Mallinckrodt ARD LLC. View original content to download multimedia: SOURCE Mallinckrodt plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-04-2025
- Business
- Yahoo
DuPont Announces Additional Leaders and Company Name for the Intended Spin-Off of the Electronics Business
Matthew Harbaugh named Chief Financial Officer; management team fully staffed ahead of spin-off Change to future Board Chair announced WILMINGTON, Del., April 29, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced Qnity Electronics, Inc. ("Qnity") as the name of the planned independent Electronics public company that will be created through the intended spin-off of its Electronics business*. As a pure-play electronics materials company, Qnity will be one of the largest and broadest solutions providers to the semiconductor and electronics industries enabling advanced computing, smart technologies and connectivity. "Inspired by 'Q', the symbol for electrical charge, and 'unity', the name reflects the collaborative way we work with customers. We harness our collective expertise, bringing energy, curiosity and quality to make tomorrow's technologies possible," said Jon Kemp, CEO-Elect of the intended Electronics spin-off. DuPont also announced that Matthew Harbaugh will join the company effective May 1, 2025, and will be the Chief Financial Officer of Qnity. Mr. Harbaugh brings more than 25 years of experience in finance, strategy, and operations management. He most recently served as CFO of Vantive, the planned spin-off from Baxter prior to its sale to Carlyle. He previously served as CFO at NuVasive and Mallinckrodt, both publicly traded companies. During his tenure at Mallinckrodt, a company that he helped spin-off from Covidien, he oversaw the company's accounting, treasury and tax functions, as well as information technology, procurement and facilities. Early in his career, Mr. Harbaugh held various finance roles with increasing responsibility first at Monsanto and then Covidien. "It's a pleasure to welcome Matt to the Qnity leadership team as our Chief Financial Officer," said Kemp, "We've assembled a tenured management team with deep industry experience, and Matt's impressive track record and experience with multiple spin-offs will bring a valuable perspective as we prepare to launch and deliver strong business results." "It is a privilege to have been selected as Qnity's future CFO at a time when the electronics industry is poised for remarkable growth and innovation," said Harbaugh. "I look forward to working alongside this highly capable team to capture the value creation opportunities for the new company and enhance shareholder returns." Additional senior leaders of the planned Electronics company include: Chuck Xu, currently Vice President in DuPont's ElectronicsCo division, will continue to lead Interconnect Solutions. Sang Ho Kang, currently Vice President in DuPont's ElectronicsCo division, will continue to lead Semiconductor Technologies. Peter Hennessey, as General Counsel; Mr. Hennessey is currently Associate General Counsel and DuPont Corporate Secretary. Kathleen Fortebuono, as Chief Human Resources Officer; Ms. Fortebuono is currently DuPont Vice President, Global Rewards, and HR M&A. Additionally, DuPont announced that Michael Stubblefield has decided not to assume the role of chairperson of the future Electronics Board of Directors. This decision will allow Mr. Stubblefield to focus on fully supporting Avantor's transition to a new CEO. A new board member for the future independent Electronics public company and the future chairperson will be named at a later date. About DuPont DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at Investors can access information included on the Investor Relations section of the website at DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. *On January 15, 2025, DuPont announced it is targeting November 1, 2025, for the completion of the intended separation of the Electronics business (the "Intended Electronics Separation"). The Intended Electronics Separation will not require a shareholder vote and is subject to satisfaction of customary conditions, including final approval by DuPont's Board of Directors, receipt of tax opinion from counsel, the completion and effectiveness of the Form 10 registration statement filed with the U.S. Securities and Exchange Commission, applicable regulatory approvals and satisfactory completion of financing. Cautionary Statement about Forward-Looking StatementsThis communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," "stabilization," "confident," "preliminary," "initial," "drive," "innovate" and similar expressions and variations or negatives of these words. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not representations or warranties or guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the ability of DuPont to effect the Intended Electronics Separation and to meet the conditions related thereto; (ii) the possibility that the Intended Electronics Separation will not be completed within the anticipated time period or at all; (iii) the possibility that the Intended Electronics Separation will not achieve its intended benefits; (iv) the impact of Intended Electronics Separation on DuPont's businesses and the risk that the separation may be more difficult, time-consuming or costly than expected, including the impact on DuPont's resources, systems, procedures and controls, diversion of management's attention and the impact and possible disruption of existing relationships with customers, suppliers, employees and other business counterparties; (v) the possibility of disruption, including disputes, litigation or unanticipated costs, in connection with the Intended Electronics Separation; (vi) the uncertainty of the expected financial performance of DuPont or the separated company following completion of the Intended Electronics Separation; (vii) negative effects of the announcement or pendency of the Intended Electronics Separation on the market price of DuPont's securities and/or on the financial performance of DuPont; (viii) the ability to achieve anticipated capital structures in connection with Intended Electronics Separation, including the future availability of credit and factors that may affect such availability; (ix) the ability to achieve anticipated credit ratings in connection with the Intended Electronics Separation; (x) the ability to achieve anticipated tax treatments in connection with the Intended Electronics Separation and completed and future, if any, divestitures, mergers, acquisitions and other portfolio changes and the impact of changes in relevant tax and other laws; (xi) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva and Chemours, including the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims; the extent and cost of ongoing remediation obligations and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (xii) indemnification of certain legacy liabilities; (xiii) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Intended Electronics Separation and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (xiv) the risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs from, among other events, pandemics and responsive actions; (xv) adverse changes in worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions; and other factors beyond DuPont's control, including inflation, recession, military conflicts, natural and other disasters or weather-related events, that impact the operations of DuPont, its customers and/or its suppliers; (xvi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (xvii) the risks associated with continuing or expanding trade disputes or restrictions, new or increased tariffs or export controls including on exports to China of U.S.-regulated products and technology; (xviii) the risks, including ability to achieve, and costs associated with DuPont's sustainability strategy, including the actual conduct of DuPont's activities and results thereof, and the development, implementation, achievement or continuation of any goal, program, policy or initiative discussed or expected; (xix) other risks to DuPont's business and operations, including the risk of impairment; and (xx) other risk factors discussed in DuPont's most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. View original content to download multimedia: SOURCE DuPont Sign in to access your portfolio
Yahoo
21-03-2025
- Business
- Yahoo
DEP issues notice of violation over Orrington mercury contamination
Mar. 20—The Department of Environmental Protection issued a notice of violation to Mallinckrodt US LLC over failing to remove mercury that has contaminated the surrounding soil for more than a decade. In the notice issued Wednesday, the DEP charges that Mallinckrodt has done an insufficient job removing the hazardous materials and has attempted to dodge its legal responsibilities surrounding the cleanup. The company, which operated a chemical manufacturing plant along the Penobscot River in Orrington between 1967 and 1982, was deemed responsible for cleaning up the river and surrounding area by a federal judge in 2015. In 2022, a judge ordered the company to pay at least $187 million to clean up the region. While under Mallinckrodt's control, the site discharged between six and 12 metric tons of mercury in the late 1960s and early 1970s, according to one court-ordered study. The plant was eventually shut down in 2000, when then-owner HoltraChem Manufacturing Co. declared bankruptcy. The department charges that Mallinckrodt has violated its orders "on an ongoing, daily basis" since at least Feb. 5, 2024, by failing to properly remove and dispose of mercury-contaminated soils. The company has also failed to provide the required corrective measures implementation plan during that time frame, the department said in its notice. The department previously ordered that all soil with mercury concentrations above 2.2 parts per million must be removed from the plant. It reminded Mallinckrodt of this rule in a June 2023 letter, according to the notice. The company replied nearly two months later, requesting a meeting to discuss potential "flexibility" in fulfilling its requirements, according to the notice. The DEP reiterated that "although meeting the 2.2 ppm ... may present technical challenges," that threshold is part of a legal order "and is therefore nonnegotiable." Months of back and forth followed, during which time the company attempted to submit insufficient cleanup plans despite warnings by the DEP, the notice said. The DEP offered modifications to Mallinckrodt's latest plan in January 2024, which the company has still not addressed, according to the notice issued Wednesday. In December, it sent a letter to the Board of Environmental Protection asking to be relieved of the department's orders, according to the notice. "Despite the requirement of the DEP Orders and repeated reminders by the DEP that Mallinckrodt remove all soils at the Site that the exceed the MPS of 2.2 ppm for mercury to protect public health, safety and the environment, Mallinckrodt has repeatedly attempted to evade this clear requirement," the DEP said in the notice Testing completed in 2023 found some soil surrounding the plant to contain as much as 12.8 ppm of mercury, according to the notice. Mallinckrodt must submit a detailed plan for removing solid materials from the remaining areas within 30 days of receiving the notice. If the DEP approves that plan or provides approval with modifications, the company will then have 15 days to begin implementing it. The department did not specify the precise consequences, including fees, it plans to pursue for Mallinckrodt. Under Maine law, failing to adhere to orders and decisions imposed by the department commissioner or Board of Environmental Protection can carry fines of between $100 and $10,000. The maximum penalty increases to $25,000 for violations involving hazardous waste, the department said in its notice. Copy the Story Link
Wall Street Journal
14-03-2025
- Business
- Wall Street Journal
Wall Street Reacts Coolly to Endo-Mallinckrodt Deal
Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim view Thursday. Shares of Endo fell more than 4% on Thursday after the company said it would merge with Mallinckrodt in a $6.7 billion deal including debt. (After emerging from bankruptcy, Dublin-based Mallinckrodt became a privately held company.)
